| BIOREM REPORTS FIRST QUARTER BOOKINGS UP 153% TO $5.2 MM |
|
|
Guelph, Ontario (May 10, 2010) – BIOREM Inc. (TSX-V: BRM) (“Biorem” or “the Company”) today announced its results for the three-month period ended March 31, 2010. Biorem’s complete fiscal 2010 first quarter financial statements and MD&A have been filed on SEDAR (www.sedar.com). “With the effects of the 2009 economic downturn behind us, our Bookings rebounded to $5.2 million in the first quarter of 2010 and are on track to meet our $18 to $20 million target for the year. Furthermore, our Backlog has increased to $12.1 million,” said Peter Bruijns, President and CEO. “We also continued expanding beyond our established leadership position in the odor control market into the growing Renewable Energy (biogas purification) and Volatile Organic Compounds (VOC) industrial sectors. We estimate the combined size of these two markets is $430 million in North America alone. We are well positioned with our proprietary best-in-class emission control systems and anticipate positive financial results for these new markets to occur in 2011.” Bookings in the first quarter of 2010 were $5,190,000, up more than 153% from $2,051,000 in the first quarter of 2009, resulting in a current Backlog of $12.1 million, up $2.0 million or 19% from December 31, 2009.
THREE MONTHS ENDED MARCH 31, 2010 Gross margin in Q1 2010 was at 35% compared to 32% in Q1 2009. The lower margin in Q1 2010 primarily relates to the under absorption of fixed costs due to lower sales levels. Although this quarter’s gross margin is below the Company’s 2008 and 2009 rate of 40%, the Company expects the 2010 annual margin to approximate the margins of the prior two years. Gross profit in Q1 2010 was $1,147,000 down slightly from $1,306,000 in Q1 2009. Total operating expenses in Q1 2010 were $1,632,000 compared to $1,332,000 in Q1 2009. The increase was primarily due to higher research and development expenses as the Company continues to advance its next generation of products in the biogas and VOC sectors and a higher commission expense that resulted from the characteristics of the current quarter’s revenue contracts. In Q1 2010, Adjusted EBITDA decreased to $(485,000) from $(27,000) in Q1 2009. The decrease was a direct result of lower revenue earned during the quarter, higher sales commissions accrued in Q1 2010 compared to Q1 2009 and increased expenditures in R&D. Net loss for the first quarter of 2010 was $892,000 or $(0.07) per basic and diluted share, compared to net loss of $425,000, or $(0.04) per basic and diluted share in the first quarter of 2009. As at March 31, 2010, the Company had working capital of $6,420,000 including cash and short-term investments of $3,092,000, trade and other receivables of $2,711,000, and unbilled revenue of $4,130,000, compared to total working capital of $7,089,000, cash and short-term investments of $4,031,000, trade and other receivables of $2,898,000, and unbilled revenue of $3,449,000 as at December 31, 2009.
About BIOREM Inc.
For further information, please contact:
James Smith, Investor Relations
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
Non-GAAP Measures Bookings and Backlog are non-GAAP measures that the Company uses to evaluate its sales performance. Bookings are those binding contracts that the Company enters into with a third party for the delivery of our products or services. As Bookings are received, the contract value (before any associated sales taxes) is included in the Backlog. The Backlog is reduced by the revenue that is recognized on each project and then adjusted for any currency changes.
|
||||||||||||||||||||||||||||||||